Navigation Links
Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
Date:5/19/2009

Agreement Underscores Morphotek's Commitment to the Development of Farletuzumab for Ovarian Cancer

Agreement Highlights Lonza's Ability to Offer Specialty Development and Manufacturing Solutions

EXTON, Pa. and BASEL, Switzerland, May 19 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Lonza Group Ltd jointly announced today that they have executed a manufacturing services agreement to support the development and manufacturing of a subset of antibodies in Morphotek's therapeutic antibody pipeline. The agreement will reserve capacity for commercial manufacturing of Morphotek's lead compound farletuzumab (also known as MORAb-003), which recently entered Phase III clinical trials for ovarian cancer under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The collaboration between both parties already encompasses several other monoclonal antibodies currently in clinical or preclinical development.

"Lonza is an ideal partner and collaborator on this project," said Philip Sass, PhD, Executive Vice President and Chief Operating Officer of Morphotek. "They have a great deal of experience and expertise with large scale expression and purification of commercial antibody products. They have demonstrated their ability to develop high-quality material and documentation with several of our programs and serve as an extension of our development team at Morphotek. Based on our working experience, we are confident that Lonza will meet our production, quality goals and timelines for our antibody programs."

"Lonza is excited to participate in supporting the commercial manufacturing of Morphotek's lead compound, farletuzumab," said Stephan Kutzer, Head of Lonza Biopharmaceuticals. "Lonza looks forward to continuing and expanding the Morphotek relationship for both development and manufacturing services using Lonza's proprietar
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
2. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
3. ImClone Systems and Lonza Walkersville to Discuss Paperless QC Micro at PDA Annual Meeting
4. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. Simcere Pharmaceutical Group Appoints Dr. Peng Wang as Chief Scientific Officer
7. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
8. Tiens Biotech Group (USA) Reports First Quarter Results
9. Adipose-derived Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Groups, Entest BioMedical Inc. Researcher
10. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
11. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Although Madison has made a deal with Georgia-based ... deployment will not be an overnight event. Certain areas will ... around Capitol Square expected to be approved by the City ... the city of Madison has taken an active role in ...
... vice president Kevin Conroy is stepping into the shoes of ... and previously held other executive roles at the company, has ... a specific purpose," Puisis said in a statement. "With a ... place, that purpose has been completed." , ,Third Wave is ...
... has tripled Third Wave Technologies ' compensation in ... $15.9 million plus legal fees. Stratagene is proceeding with ... after the judge found that Stratagene willfully infringed on ... Third Wave $5.3 million. , ,Third Wave uses the ...
Cached Biology Technology:Madison wireless deal goes forward with Cellnet 2
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... in immune cells may be a reliable marker for ... appearing in the July issue of Molecular and ... and complex psychiatric illness that affects about 1% of ... and the assessment of ambiguous symptoms, which frequently leads ...
... JULY 7, 2008 -- The Soil Science Society of ... Sherrod Brown and his colleagues in the Senate who ... "essential" natural resource, placing soil on par with water ... joined by co-sponsoring Senators Kent Conrad (D-ND), Charles Grassley ...
... The effective treatment of many forms of cancer continues ... fail to respond to standard forms of chemotherapy or ... Centre for Infection Research (HZI) in Braunschweig, the Hannover ... now discovered a chemical mechanism with which a natural ...
Cached Biology News:Senate resolution shines spotlight on the importance of soils 2Argyrin: Natural substance raises hope for new cancer therapies 2
GLP-1 (HYB 147-12)...
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Kit containing positive control DNA all parts of the HIV-1 genome, HIV-1 negative control DNA, Primers SK38, SK39, SK19...
Biology Products: